ValuEngine Downgrades GlaxoSmithKline (GSK) to Hold
ValuEngine lowered shares of GlaxoSmithKline (NYSE:GSK) from a buy rating to a hold rating in a research report released on Friday morning.
Several other research analysts also recently weighed in on GSK. JPMorgan Chase & Co. reiterated a neutral rating on shares of GlaxoSmithKline in a research note on Tuesday, October 24th. Zacks Investment Research downgraded GlaxoSmithKline from a buy rating to a hold rating in a research note on Wednesday, January 10th. Investec downgraded GlaxoSmithKline from a buy rating to a hold rating in a research note on Monday, November 6th. TheStreet upgraded GlaxoSmithKline from a c+ rating to a b rating in a research note on Wednesday, October 25th. Finally, Bank of America downgraded GlaxoSmithKline from a buy rating to a neutral rating in a research note on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the company’s stock. GlaxoSmithKline has an average rating of Hold and an average price target of $38.57.
GlaxoSmithKline (GSK) opened at $36.48 on Friday. The stock has a market capitalization of $91,969.94, a price-to-earnings ratio of 30.41, a price-to-earnings-growth ratio of 2.30 and a beta of 0.98. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. GlaxoSmithKline has a 12 month low of $34.52 and a 12 month high of $44.53.
ILLEGAL ACTIVITY NOTICE: “ValuEngine Downgrades GlaxoSmithKline (GSK) to Hold” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/05/valuengine-downgrades-glaxosmithkline-gsk-to-hold.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.